[Treatment of epithelial thymic tumours: towards a multidisciplinary management].
BACKGROUND
Thymic epithelial tumours (TET) are rare. Their optimal management is still not well defined on account of their rarity and the consequent difficulty of clinical research into the subject. This review presents the current clinical and therapeutic data, emphasising the need for a multidisciplinary management of advanced stage TET.


BACKGROUND
Three situations may be defined: localised tumours requiring radical surgery following a careful search for associated paraneoplastic syndromes; tumours with capsular invasion requiring surgery and adjuvent radiotherapy; advanced stage TET where only multimodal treatment is capable of improving the prognosis by increasing the percentage of complete resections while optimising local control with adjuvent radiotherapy.


CONCLUSIONS
An evaluation of the multimodal strategies for the treatment of advanced stage TET requires the establishment of multidisciplinary collaborative trials. The contribution of new therapies, somatostatin analogues and targeted therapies needs to be defined.


CONCLUSIONS
The management of advanced stage TET should rest upon a multidisciplinary dialogue between a team of specialists, ideally in the framework of collaborative trials.
Jacot
W
W
Service des Maladies Respiratoires, Hôpital Arnaud de Villeneuve, Centre Hospitalier Universitaire de Montpellier, France.
Quantin
X
X
Pujol
J-L
JL
D002277:Carcinoma / Q000145:classification / Q000175:diagnosis / Q000628:therapy*; D003131:Combined Modality Therapy; D018450:Disease Progression; D006801:Humans; D011379:Prognosis; D013953:Thymus Neoplasms / Q000145:classification / Q000175:diagnosis / Q000628:therapy*